Megpro 40 Tablet contains Megestrol acetate 40 mg, a synthetic derivative of the hormone progesterone. It is primarily indicated for the management of anorexia, cachexia, or significant unexplained weight loss in patients with chronic illnesses such as cancer or acquired immunodeficiency syndrome (AIDS). Megestrol acts by stimulating appetite and promoting weight gain through its progestational and antineoplastic properties. The tablet is administered orally and dosage should be individualized based on the patient’s clinical condition and response to therapy. Megpro 40 is also utilized as an adjunct in the palliative treatment of advanced breast and endometrial carcinoma due to its anti-estrogenic effects. Common adverse effects include nausea, vomiting, edema, thromboembolic phenomena, and adrenal suppression; therefore, monitoring for these is advised during prolonged therapy. Caution is warranted in patients with a history of thromboembolic disorders, diabetes mellitus, or hepatic impairment. Megpro 40 should be used under strict medical supervision, and patients should be regularly assessed to evaluate therapeutic efficacy and tolerability. It is contraindicated in pregnancy due to potential teratogenic effects. Overall, Megpro 40 Tablet is a valuable pharmacological option for appetite stimulation and hormone-responsive malignancies.